LeukoPrint®
Hematologic Malignancy Molecular Karyotyping Test
LeukoPrint® is a molecular karyotyping test designed to complement conventional cytogenetic approaches in hematologic malignancy diagnostics. lt employs shallow whole-genome sequencing (sWGS) to deliver comprehensive, high-resolution genome coverage for the detection of clinically significant copy number aberration (CNA) and copy neutral loss of heterozygosity (CN-LOH), providing advantages over traditional karyotyping and fluorescence in situ hybridization (FlSH).
Molecular karyotyping
Precision diagnosis
Risk stratification
Therapy guidance
How it works
- LeukoPrint® performs shallow whole-genome sequencing (sWGS, at 1× coverage) on bone marrow samples to identify genome-wide CNA and CN-LOH.
- When combined with traditional cytogenetic methods, it enables more accurate diagnosis,classification, risk-stratification, and ultimately guides risk-adapted therapy for hematologic malignancies.
When to use LeukoPrint® test
First-line diagnostic adjunct
enhances sensitivity in
suspected hematologic
malignancies.
Karyotyping failure rescue
provides full genomic profiling when standard
karyotyping fails.
Complex case resolution
reveals cryptic abnormalities when karyotyping/FISH
are inconclusive.
Critical variant detection
identifies CN-LOH
undetectable by
karyotyping/FISH.
How does the process work
Customer order
Customers can place orders through SeekIn official website or local agents
Blood-draw
2-4ml bone marrow collected in EDTA tubes and ransport under refrigeration
Testing
Detection by next generation sequencing (NGS) platform
Reporting
The test results will be ready in about 10 workdays after your blood draw arrived at central lab
